Medicare Spends Billions on Oncology Drugs Offering Little Added Benefit

MedPage Today) — In an analysis of Medicare’s top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no added benefit.
In 2022, Medicare…